mCRPC VL

The Process of Metastasis in Prostate Cancer - Kenneth Pienta

Details
(Length of Discussion: 16 min) Charles Ryan and Ken Pienta discuss the process of metastasis in prostate cancer, referring to the seed and soil hypothesis and the influence of the tumor microenvironment and immune system. Biography: Kenneth J. Pienta, MD, The Donald S. Coffey Professor of Urology, Professor of Oncology, Professor of Pharmacology and Molecular Sciences, The Johns Hopkins Hospital R...

An Update on the PARP Inhibitor Olaparib in mCRPC Patients: Review of the Phase 2 Results & A First Look at the Phase 3 Study.

Details
Noel Clarke shares a recent update in his work focused on the PARP inhibitor, olaparib for patients with castration-resistant prostate cancer (CRPC) in combination with abiraterone. Biographies: Noel W Clarke, Professor of Urologic Oncology, Director of the Genitourinary Research Group, Manchester University, Consultant Urologist at Salford Royal Hospital and The Christie, Manchester Charles J. Ry...

Combination Therapies and Quality of Life Data in Prostate Cancer - Fred Saad

Details
Charles Ryan and Fred Saad discuss the data results in patients with mCRPC from a combined therapeutic approach with abiraterone and apalutamide. They discuss the rationale and theory behind these results. They move to discuss the quality of life analysis for patients with CRPC. A review of the SPARTAN trial and the optimistic results from his work. Biographies: Fred Saad MD FRCS is a full-time pr...

Prospective Study of Low-Dose Abiraterone with Food Versus Standard Dose Abiraterone in mCRPC - Russell Szmulewitz

Details
(Length of Discussion: 21 min) Russell Szmulewitz talks with Alicia Morgans about a trial that evaluated abiraterone with food and how that might affect relative patient outcomes, such as PSA. This study sought to test the hypothesis that low-dose Abiraterone acetate (AA) (LOW; 250 mg with a low-fat meal) would have comparable activity to standard dosed AA (STD; 1,000 mg fasting) in patients with...

Exercise in Men with Metastatic Castrate-Resistant Prostate Cancer, the INTERVAL Study - Interview with Fred Saad

Details
Fred Saad and Charles Ryan discuss the Movember Foundation sponsored, INTense Exercise foR surVivAL Among Men With Metastatic Castrate-Resistant Prostate Cancer Study (INTERVAL). This is a randomized phase 3 study of exercise in men with metastatic castrate-resistant prostate cancer (mCRPC). The objective of the study is to determine if high intensity aerobic and resistance training plus psychosoc...

UPWARD Study - Seizure Rates in Enzalutamide-Treated Men with mCRPC - Susan Slovin

Details
(Length of presentation: 17 min) Alicia Morgans, MD discusses the UPWARD Study with Susan Slovin, MD, PhD. A study Dr. Slovin was a part of conducting to answer the question “Are seizure rates affected by treatment with enzalutamide in patients with metastatic castration-resistant prostate cancer who have seizure risk factors?” Dr. Slovin discusses with Dr. Morgans the reasons for conducting the U...